This article was originally published in The Gray Sheet
Executive SummaryMaker of microfluidic systems for detection and analysis of nucleic acids raises $34.5 mil. in its initial public offering, the company announces July 13 (1"The Gray Sheet" July 3, p. 11). With exercise of 750,000 over-allotment shares by underwriters UBS Warburg, Prudential Vector Healthcare and Invemed Associates, the IPO included a total of 5.75 mil. shares at $6 each. Proceeds will be used for R&D and expansion of manufacturing. Cepheid shares trade on the Nasdaq exchange under the symbol "CPHD"
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).